Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report.
Adjuvants, Immunologic
/ administration & dosage
Administration, Intravesical
BCG Vaccine
/ immunology
Comorbidity
Disease Progression
Drug Administration Schedule
Eosinophils
/ immunology
Female
Humans
Immunotherapy
/ methods
Lymphocytes
/ immunology
Male
Middle Aged
Neoplasm Recurrence, Local
/ immunology
Neutrophils
/ immunology
Retrospective Studies
Urinary Bladder Neoplasms
/ immunology
BCG
Eosinophils
Local neoplasm recurrence
Urinary bladder neoplasms
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
21
05
2020
accepted:
15
07
2020
pubmed:
24
7
2020
medline:
30
1
2021
entrez:
24
7
2020
Statut:
ppublish
Résumé
To determine whether there is an association between blood eosinophil count and percentage with the recurrence of nonmuscle invasive bladder cancer (NMIBC) during Bacillus Calmette-Guérin (BCG) maintenance therapy with our preliminary results. A total of 53 patients with NMIBC underwent BCG immunotherapy between January 2015 and September 2018, and met our inclusion criteria were included in the study. The parameters age, gender, smoking status, comorbidity, blood neutrophil, lymphocyte and eosinophil counts, blood eosinophil percentage, previous single postoperative intravesical chemotherapy instillation, tumor characteristic, and total and maintenance dose numbers of BCG were extracted from our medical records and compared between patients with response and with recurrence. Blood eosinophil count and percentage were significantly higher in patients with recurrence compared to patients with response (0.263 ± 0.37 vs. 0.0134 ± 0.021, p = 0.01 and 0.31 ± 0.29 vs. 0.17 ± 0.27, p = 0.01). Other parameters were similar in patients with recurrence and response. Receiver-operating characteristic analysis showed a considerable diagnostic value of blood eosinophil count and percentage in the prediction of bladder cancer recurrence during BCG immunotherapy. Blood eosinophil count and percentage in patients with NMIBC can predict the disease recurrence during the BCG immunotherapy. Our research raised new questions and assumptions about the role of eosinophils during BCG immunotherapy.
Identifiants
pubmed: 32700089
doi: 10.1007/s00262-020-02673-x
pii: 10.1007/s00262-020-02673-x
doi:
Substances chimiques
Adjuvants, Immunologic
0
BCG Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-252Références
Kang M, Jeong CW, Kwak C, Kim HH, Ku JH (2017) Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget 8:12891–12901. https://doi.org/10.18632/oncotarget.14179
doi: 10.18632/oncotarget.14179
pubmed: 28039452
Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y (2017) Bladder cancer. Nat Rev Dis Primers 3:17022. https://doi.org/10.1038/nrdp.2017.22
doi: 10.1038/nrdp.2017.22
Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moskovitz B, van der Heijden AG, Witjes JA (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus calmette-guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69:1046–1052. https://doi.org/10.1016/j.eururo.2016.01.006
doi: 10.1016/j.eururo.2016.01.006
pubmed: 26803476
Nunez-Nateras R, Castle EP, Protheroe CA et al (2014) Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol 32(45):e23–30. https://doi.org/10.1016/j.urolonc.2013.06.008
doi: 10.1016/j.urolonc.2013.06.008
Zlotta AR, Fleshner NE, Jewett MA (2009) The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3:S199–205
doi: 10.5489/cuaj.1196
Kamat AM, Li R, O'Donnell MA et al (2018) Predicting response to intravesical bacillus Calmette-Guerin immunotherapy: are we there yet? A systematic review. Eur Urol 73:738–748. https://doi.org/10.1016/j.eururo.2017.10.003
doi: 10.1016/j.eururo.2017.10.003
pubmed: 29055653
Prakash Babu S, Narasimhan PB, Babu S (2019) Eosinophil polymorphonuclear leukocytes in TB: what we know so far. Front Immunol 10:2639. https://doi.org/10.3389/fimmu.2019.02639
doi: 10.3389/fimmu.2019.02639
pubmed: 31798582
pmcid: 6868031
Kirman J, Zakaria Z, McCoy K, Delahunt B, Le Gros G (2000) Role of eosinophils in the pathogenesis of Mycobacterium bovis BCG infection in gamma interferon receptor-deficient mice. Infect Immun 68:2976–2978. https://doi.org/10.1128/iai.68.5.2976-2978.2000
doi: 10.1128/iai.68.5.2976-2978.2000
pubmed: 10768997
pmcid: 97512
Castro AG, Esaguy N, Macedo PM, Aguas AP, Silva MT (1991) Live but not heat-killed mycobacteria cause rapid chemotaxis of large numbers of eosinophils in vivo and are ingested by the attracted granulocytes. Infect Immun 59:3009–3014
doi: 10.1128/IAI.59.9.3009-3014.1991
Montironi R, Lopez-Beltran A (2005) The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 13:143–153. https://doi.org/10.1177/106689690501300203
doi: 10.1177/106689690501300203
pubmed: 15864376
Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB (2018) Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol 73:560–569. https://doi.org/10.1016/j.eururo.2017.12.018
doi: 10.1016/j.eururo.2017.12.018
Johnston LK, Bryce PJ (2017) Understanding interleukin 33 and its roles in eosinophil development. Front Med 4:51. https://doi.org/10.3389/fmed.2017.00051
doi: 10.3389/fmed.2017.00051
Rosenberg HF, Dyer KD, Foster PS (2013) Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13:9–22. https://doi.org/10.1038/nri3341
doi: 10.1038/nri3341
Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G, Mattei F, Marone G, Schiavoni G (2018) Eosinophils: the unsung heroes in cancer? Oncoimmunology 7:e1393134. https://doi.org/10.1080/2162402X.2017.1393134
doi: 10.1080/2162402X.2017.1393134
pubmed: 29308325
Bochner BS (2015) Novel therapies for eosinophilic disorders. Immunol Allergy Clin N Am 35:577–598. https://doi.org/10.1016/j.iac.2015.05.007
doi: 10.1016/j.iac.2015.05.007
Lucarini V, Ziccheddu G, Macchia I et al (2017) IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology 6:e1317420. https://doi.org/10.1080/2162402X.2017.1317420
doi: 10.1080/2162402X.2017.1317420
pubmed: 28680750
pmcid: 5486175
Horiuchi T, Weller PF (1997) Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 17:70–77. https://doi.org/10.1165/ajrcmb.17.1.2796
doi: 10.1165/ajrcmb.17.1.2796
pubmed: 9224211
Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934
doi: 10.1016/S0021-9258(19)49853-0
Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, Felding P, de Fine ON, Bjerrum OW (2014) Eosinophilia in routine blood samples as a biomarker for solid tumor development - a study based on the Copenhagen Primary Care Differential Count (CopDiff) Database. Acta Oncol 53:1245–1250. https://doi.org/10.3109/0284186X.2014.887857
doi: 10.3109/0284186X.2014.887857
pubmed: 24913152
Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belda MA, Diez G, de Medina S, Abbou CC, Chopin DK (2001) Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guerin treatment. BJU Int 88:602–610
doi: 10.1046/j.1464-410X.2001.02394.x
Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, Gander H, Rahm A, Thurnher M (2017) Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother CII 66:427–440. https://doi.org/10.1007/s00262-016-1945-z
doi: 10.1007/s00262-016-1945-z
pubmed: 28005163
Miyata Y, Sakai H (2015) Predictive markers for the recurrence of nonmuscle invasive bladder cancer treated with intravesical therapy. Dis Mark 2015:857416. https://doi.org/10.1155/2015/857416
doi: 10.1155/2015/857416
Diny NL, Rose NR, Cihakova D (2017) Eosinophils in autoimmune diseases. Front Immunol 8:484. https://doi.org/10.3389/fimmu.2017.00484
doi: 10.3389/fimmu.2017.00484
pubmed: 28496445
pmcid: 5406413
Caldwell JM, Collins MH, Stucke EM, Putnam PE, Franciosi JP, Kushner JP, Abonia JP, Rothenberg ME (2014) Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol 134:1114–1124. https://doi.org/10.1016/j.jaci.2014.07.026
doi: 10.1016/j.jaci.2014.07.026
pubmed: 25234644
pmcid: 4254306
Lowe D, Fletcher CD, Gower RL (1984) Tumour-associated eosinophilia in the bladder. J Clin Pathol 37:500–502
doi: 10.1136/jcp.37.5.500
Driss V, Legrand F, Hermann E et al (2009) TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins. Blood 113:3235–3244. https://doi.org/10.1182/blood-2008-07-166595
doi: 10.1182/blood-2008-07-166595
pubmed: 18978205
Borelli V, Vita F, Shankar S, Soranzo MR, Banfi E, Scialino G, Brochetta C, Zabucchi G (2003) Human eosinophil peroxidase induces surface alteration, killing, and lysis of Mycobacterium tuberculosis. Infect Immun 71:605–613
doi: 10.1128/IAI.71.2.605-613.2003
Siracusano S, Vita F, Abbate R, Ciciliato S, Borelli V, Bernabei M, Zabucchi G (2007) The role of granulocytes following intravesical BCG prophylaxis. Eur Urol 51:1589–1597. https://doi.org/10.1016/j.eururo.2006.11.045 (discussion 97–99)
doi: 10.1016/j.eururo.2006.11.045
pubmed: 17222501
Durrington HJ, Gioan-Tavernier GO, Maidstone RJ et al (2018) Time of day affects eosinophil biomarkers in asthma: implications for diagnosis and treatment. Am J Respir Crit Care Med 198:1578–1581. https://doi.org/10.1164/rccm.201807-1289LE
doi: 10.1164/rccm.201807-1289LE
pubmed: 30156881
pmcid: 6298638
Sennels HP, Jorgensen HL, Hansen AL, Goetze JP, Fahrenkrug J (2011) Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Investig 71:532–541. https://doi.org/10.3109/00365513.2011.602422
doi: 10.3109/00365513.2011.602422
Wu HX, Zhuo KQ, Cheng DY (2019) Peripheral blood eosinophil as a biomarker in outcomes of acute exacerbation of chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis 14:3003–3015. https://doi.org/10.2147/COPD.S226783
doi: 10.2147/COPD.S226783
Pavord ID, Agusti A (2016) Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. Eur Respir J 47:1299–1303. https://doi.org/10.1183/13993003.00055-2016
doi: 10.1183/13993003.00055-2016
pubmed: 27132257
Bafadhel M, Pavord ID, Russell REK (2017) Eosinophils in COPD: just another biomarker? Lancet Respir Med 5:747–759. https://doi.org/10.1016/S2213-2600(17)30217-5
doi: 10.1016/S2213-2600(17)30217-5
pubmed: 28601554
Onesti CE, Josse C, Poncin A, Freres P, Poulet C, Bours V, Jerusalem G (2018) Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget 9:33719–33733. https://doi.org/10.18632/oncotarget.26120
doi: 10.18632/oncotarget.26120
pubmed: 30263098
pmcid: 6154746
Moreira A, Leisgang W, Schuler G, Heinzerling L (2017) Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy 9:115–121. https://doi.org/10.2217/imt-2016-0138
doi: 10.2217/imt-2016-0138
pubmed: 28128709
Sylman JL, Mitrugno A, Atallah M et al (2018) The predictive value of inflammation-related peripheral blood measurements in cancer staging and prognosis. Front Oncol 8:78. https://doi.org/10.3389/fonc.2018.00078
doi: 10.3389/fonc.2018.00078
pubmed: 29619344
pmcid: 5871812